This is not the most recent version of the article. View current version (15 FEB 2012)

Intervention Review

Lobeline for smoking cessation

  1. Lindsay F Stead1,*,
  2. John R Hughes2

Editorial Group: Cochrane Tobacco Addiction Group

Published Online: 21 JUL 1997

Assessed as up-to-date: 7 JAN 2009

DOI: 10.1002/14651858.CD000124


How to Cite

Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database of Systematic Reviews 1997, Issue 3. Art. No.: CD000124. DOI: 10.1002/14651858.CD000124.

Author Information

  1. 1

    University of Oxford, Department of Primary Health Care, Oxford, UK

  2. 2

    University of Vermont, Human Behavioral Pharmacology Lab, Dept of Psychiatry, Burlington, Vermont, USA

*Lindsay F Stead, Department of Primary Health Care, University of Oxford, Rosemary Rue Building, Old Road Campus, Oxford, OX3 7LF, UK. lindsay.stead@dphpc.ox.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 21 JUL 1997

SEARCH

This is not the most recent version of the article. View current version (15 FEB 2012)

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.

Objectives

The objective of this review was to assess the effects of lobeline on long term smoking cessation.

Search methods

We searched the Cochrane Tobacco Addiction Group trials register (most recent search January 2009).

Selection criteria

Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.

Data collection and analysis

We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.

Main results

We identified no trials meeting the full inclusion criteria including long term follow-up.

Authors' conclusions

There is no evidence available from long term trials that lobeline can aid smoking cessation.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Can lobeline help people to quit smoking

Lobeline is an alkaloid derived from the leaves of an Indian tobacco plant, and has been widely used in commercial smoking remedies. Its adverse effects include dizziness, nausea, and vomiting, and tablets and pastilles containing Lobeline may lead to throat irritation. The review found no adequate long-term trials which could provide evidence that Lobeline can help people stop smoking. Even short-term studies do not indicate a consistent effect on smoking behaviour.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

使用Lobeline戒菸

Lobeline是一種尼古丁感受器的局部促動劑(partial agonist),在產業上已被廣泛地以多種配製形式,使用於戒菸。

目標

本篇回顧文獻的主要目的,是為了評估Lobeline在長期戒菸的療效。

搜尋策略

我們搜尋了低Cochrane Tobacco Addiction Group trials register(其中最新的相關研究是發表於2006年4月)。

選擇標準

被納入的研究包含了Lobeline與安慰劑或其他的替代療法(至少可維持戒菸效果六個月的療法)的隨機分配比較研究。

資料收集與分析

我們選取複本資料,包括受試的者類別、Lobeline的劑量與形式、測量的結果、隨機分配的方法,以及是否完成追蹤。

主要結論

包括長期的追蹤研究,我們並未發現有任何研究,完全符合上述的研究納入標準。

作者結論

從長期的追蹤研究中,並無足夠的證據顯示,Lobeline可協助戒菸。

翻譯人

本摘要由彰化基督教醫院鄭怡君翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

研究中並無證據顯示Lobeline可協助人們戒菸。Lobeline是印度菸葉的鹼性淬取物,已在產業上廣泛地使用於治療吸菸。Lobeline的副作用包括頭暈、噁心以及嘔吐。此外含有Lobeline的錠劑或是粉狀物亦可引發刺激喉嚨。本回顧文獻發現,並無適當及長期的研究可證實Lobeline協助人們戒菸的證據。即便在短期的研究中,Lobeline於吸菸行為的影響上,亦未呈現一致的結果。